We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 112

IP monitor - a healthy development? A review of CIPO’s new “medical method” examination guidelines

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 31 2015

On March 18, 2015 the Canadian Intellectual Property Office (“CIPO”) issued a Patent Notice: Revised Examination Practice Respecting Medical Uses

Federal Court declares omeprazole formulation patent valid and infringed

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 25 2015

On March 16, 2015, Justice Barnes of the Federal Court issued his decision in AstraZeneca Canada Inc. et al v. Apotex Inc., 2015 FC 322, declaring

Patents found obvious; subsequent appeal moot

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 6 2015

Janssen Inc (Janssen) brought two Applications pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for orders

Federal Court of Appeal holds PMNOC appeal moot - innovator argument on CETA equal access to appeal right rejected

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 12 2015

Janssen Inc. et al. (Janssen) appealed from the decision of Justice Barnes of the Federal Court refusing to prohibit the Minister of Health from

Federal Court rejects generic’s non-infringing alternative defence and awards compound interest for patent infringement damages

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 2 2015

On January 23, 2015, the Federal Court released its public reasons for Judgment granting Eli Lilly and Company and Eli Lilly Canada, Inc

Generic companies seek leave to appeal to the Supreme Court of Canada on the “promise of the patent”

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • January 9 2015

On December 23, 2014, Apotex Inc. and Mylan Pharmaceuticals ULC each filed Supreme Court of Canada (SCC) applications for leave to appeal the Federal

Cadeau de Noël?

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • December 18 2014

Nous avions parlé dans ce billet des importants changements proposés à la Loi sur les brevets par le projet de loi C-43 ? Eh bien, le projet de loi a

Do patents liquefy stocks? Patents, trade secrets and impacts on the marketplace

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • December 5 2014

Intellectual Property professionals, and owners of intellectual property (IP) rights, generally agree on the important value of patents. A relevant

Patent term restoration for Canadian pharmaceutical patents

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • November 28 2014

The signature of the free-trade agreement texts between Canada and the European Union provided additional details on the provisions relating to the

New developments on the patent “utility” debate in Canada

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

There have been a number of notable developments in recent weeks in respect of patent utility law in Canada